St. Jude Medical Expands Presence In Electrophysiology Market With New Advanced Ablation Catheter
St. Jude Medical expands its presence in the electrophysiology market after gaining European regulatory approval of FlexAbility, the company’s next-generation flexible ablation catheter, and expects to receive US FDA 510(k) clearance for the device by year-end.
You may also be interested in...
The company will be recruiting around 1,450 patients at 50 U.S. sites during the next four to five years to prove its ablation therapy is a valuable addition to ICDs or CRT-Ds to reduce recurrent ventricular tachycardia.
Groundbreaking new mapping technologies could shift the future direction of the $2.5 billion AF ablation market, as evidenced by presentations at this year’s HRS and EUROPACE meetings; with some compelling clinical data now on the books, the electrophysiologists who perform AF ablation are taking notice, as are investors and strategics operating in this space. Emerging companies at the heart of this shift include Topera Medical, CardioInsight Technologies, and Acutus Medical.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.